Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.
- Conditions
- Lung Neoplasms
- First Posted Date
- 2003-01-14
- Last Posted Date
- 2006-07-20
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00051506
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Charleston, South Carolina, United States
ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2003-01-14
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT00051493
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2003-01-09
- Last Posted Date
- 2007-06-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 107
- Registration Number
- NCT00051298
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Moscow, Russian Federation
🇺🇸For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Cerritos, California, United States
Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying
- First Posted Date
- 2002-12-18
- Last Posted Date
- 2007-11-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2
- Registration Number
- NCT00050609
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saskatoon, Saskatchewan, Canada
Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder
- Conditions
- Bipolar Disorder
- First Posted Date
- 2002-11-27
- Last Posted Date
- 2007-06-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 130
- Registration Number
- NCT00050206
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Indianapolis, Indiana, United States
A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)
- Conditions
- Sepsis
- First Posted Date
- 2002-11-15
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2000
- Registration Number
- NCT00049777
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician, Berlin, Germany
Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis
- First Posted Date
- 2002-11-14
- Last Posted Date
- 2007-11-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 474
- Registration Number
- NCT00049764
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Southhampton, United Kingdom
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
- Conditions
- Osteoporosis, Postmenopausal
- First Posted Date
- 2002-09-23
- Last Posted Date
- 2006-07-20
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00046137
- Locations
- 🇺🇸
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician"., Dallas, Texas, United States
The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis
- Conditions
- Sepsis
- First Posted Date
- 2002-09-10
- Last Posted Date
- 2006-07-20
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00045760
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Northampton, United Kingdom
🇺🇸timoreFor additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Baltimore, Maryland, United States
🇬🇧For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., London, United Kingdom
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
- Conditions
- Colorectal NeoplasmsMetastases, Neoplasm
- Interventions
- Biological: Erbitux (Cetuximab)
- First Posted Date
- 2002-09-09
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT00044863
- Locations
- 🇺🇸
ImClone Investigational Site, St. Charles, Missouri, United States